|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
5,560,000,000 |
Market
Cap: |
162.96(B) |
Last
Volume: |
38,164,433 |
Avg
Vol: |
30,564,972 |
52
Week Range: |
$25.26 - $40.28 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
|
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 6.5 |
Insider 3/6 Months : 7.1 |
|
Guru Rank Number : 710 |
Guru Rank Value : 1.7 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Pfizer is a research-based biopharmaceutical company. Co. is engaged in the discovering, developing, manufacturing, marketing, sales and distribution of biopharmaceutical products. Co.'s business includes: internal medicine, which includes cardiovascular metabolic and pain products; oncology, which includes products in biologics, small molecules, immunotherapies, and biosimilars for cancers; hospital, which includes Co.'s portfolio of sterile injectable and anti-infective medicines, as well as Pfizer CentreOne; vaccines, which includes vaccines brands in pneumococcal disease, meningococcal disease, tick-borne encephalitis and COVID-19; inflammation and immunology; and rare disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
3,000 |
3,000 |
5,000 |
Total Buy Value |
$0 |
$79,401 |
$79,401 |
$156,406 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
3 |
Total Shares Sold |
0 |
0 |
0 |
14,130 |
Total Sell Value |
$0 |
$0 |
$0 |
$624,281 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Susman Sally |
Executive Vice President |
|
2024-02-23 |
4 |
OE |
$27.34 |
$1,745,304 |
D/D |
63,837 |
218,148 |
|
- |
|
Bourla Albert |
Chairman & CEO |
|
2024-02-23 |
4 |
D |
$27.37 |
$3,069,130 |
D/D |
(112,009) |
327,739 |
|
- |
|
Bourla Albert |
Chairman & CEO |
|
2024-02-23 |
4 |
OE |
$27.34 |
$3,490,607 |
D/D |
127,674 |
439,748 |
|
- |
|
Mcdermott Michael |
Executive Vice President |
|
2024-02-23 |
4 |
D |
$27.37 |
$298,394 |
D/D |
(10,890) |
84,518 |
|
- |
|
Mcdermott Michael |
Executive Vice President |
|
2024-02-23 |
4 |
OE |
$27.34 |
$339,344 |
D/D |
12,412 |
95,408 |
|
- |
|
Boshoff Christoffel |
Executive Vice President |
|
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
34,734 |
137,296 |
|
- |
|
Gottlieb Scott |
Director |
|
2023-12-15 |
4 |
B |
$26.47 |
$79,401 |
D/D |
3,000 |
9,000 |
2.39 |
-4% |
|
Boshoff Christoffel |
Executive Vice PresidentOffice |
|
2023-07-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
605 |
|
-19% |
|
Boshoff Christoffel |
Executive Vice PresidentOffice |
|
2023-07-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
101,554 |
|
-19% |
|
Denton David M |
Chief Financial Officer & EVP |
|
2023-05-31 |
4 |
D |
$38.02 |
$616,798 |
D/D |
(16,223) |
48,224 |
|
- |
|
Gottlieb Scott |
Director |
|
2023-05-08 |
4 |
B |
$38.58 |
$38,580 |
D/D |
1,000 |
6,000 |
2.39 |
-12% |
|
Gottlieb Scott |
Director |
|
2023-05-05 |
4 |
B |
$38.43 |
$38,425 |
D/D |
1,000 |
5,000 |
2.39 |
-11% |
|
Damico Jennifer B. |
SVP & Controller |
|
2023-03-15 |
4 |
S |
$40.02 |
$396,678 |
D/D |
(9,912) |
9,003 |
|
8% |
|
Damico Jennifer B. |
SVP & Controller |
|
2023-02-27 |
4 |
D |
$40.78 |
$58,193 |
D/D |
(1,427) |
19,275 |
|
- |
|
Mcdermott Michael |
Executive Vice President |
|
2023-02-27 |
4 |
D |
$40.78 |
$125,643 |
D/D |
(3,081) |
80,874 |
|
- |
|
Sahni Payal |
Executive Vice President |
|
2023-02-27 |
4 |
D |
$40.78 |
$52,892 |
D/D |
(1,297) |
23,077 |
|
- |
|
Damico Jennifer B. |
SVP & Controller |
|
2023-02-25 |
4 |
D |
$41.75 |
$308,603 |
D/D |
(7,191) |
20,702 |
|
- |
|
Damico Jennifer B. |
SVP & Controller |
|
2023-02-25 |
4 |
OE |
$22.89 |
$255,224 |
D/D |
11,150 |
27,893 |
|
- |
|
Lankler Douglas M |
Executive Vice President |
|
2023-02-25 |
4 |
D |
$41.75 |
$1,101,741 |
D/D |
(26,389) |
135,146 |
|
- |
|
Hwang Angela |
President, Global Biopharma |
|
2023-02-25 |
4 |
D |
$41.75 |
$631,591 |
D/D |
(14,763) |
29,778 |
|
- |
|
Hwang Angela |
President, Global Biopharma |
|
2023-02-25 |
4 |
OE |
$22.89 |
$464,049 |
D/D |
20,273 |
44,541 |
|
- |
|
Mcdermott Michael |
Executive Vice President |
|
2023-02-25 |
4 |
D |
$41.75 |
$392,417 |
D/D |
(9,144) |
83,955 |
|
- |
|
Mcdermott Michael |
Executive Vice President |
|
2023-02-25 |
4 |
OE |
$22.89 |
$324,534 |
D/D |
14,178 |
93,099 |
|
- |
|
Bourla Albert |
Chairman & CEO |
|
2023-02-25 |
4 |
D |
$41.75 |
$1,812,743 |
D/D |
(43,419) |
309,058 |
|
- |
|
Dolsten Mikael |
President R&D |
|
2023-02-25 |
4 |
D |
$41.75 |
$1,548,007 |
D/D |
(37,078) |
354,145 |
|
- |
|
1391 Records found
|
|
Page 2 of 56 |
|
|